A Case Report of Rituximab Induced AngioedemaCorrespondence Address :
Dr. Karan Shah,
2nd Year Resident, Department of Pharmacology, Smt. NHL Municipal Medical College, Ellisbridge,
Ahmedabad-380006, Gujarat, India.
Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. It has been approved for rheumatoid arthritis and is a promising new agent in the treatment of several autoimmune neurological disorders and also Sjögren’s syndrome. Common adverse reactions to treatment with Rituximab include infusion reactions including angioedema and hypersensitivity reactions. In the present case, we observed severe angioedema after low dose of Rituximab therapy. Clinicians should be vigilant when using Rituximab for such hypersensitivity phenomenon occurring despite pre-medicating with glucocorticoids.
Hypersensitivity reactions, Rheumatology, Sjögren’s syndrome
Dhaivat Shukla, Karan Shah, Sapan Pandya, Supriya Malhotra, Pankaj Patel. A CASE REPORT OF RITUXIMAB INDUCED ANGIOEDEMA. Journal of Clinical and Diagnostic Research [serial online] 2018 September [cited: 2018 Sep 18 ]; 12:OD03-OD04. Available from
Date of Submission: Jan 16, 2018
Date of Peer Review: Mar 31, 2018
Date of Acceptance: Jun 25, 2018
Date of Publishing: Sep 01, 2018
FINANCIAL OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2016: 132.37
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase & EMbiology
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)